The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The clinical impact of early immunological responses in human HER2-positive breast cancers on responsiveness to trastuzumab-based therapy.
 
Alex J Eustace
No Relationships to Disclose
 
Sinead Toomey
Speakers' Bureau - Roche/Genentech
 
Joanna Fay
No Relationships to Disclose
 
Ausra Teiserkiene
No Relationships to Disclose
 
Malgorzata Milewska
Research Funding - Bayer (Inst)
 
Elaine Kay
Consulting or Advisory Role - Almac Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - DUBLIN CITY UNIVERSITY (Inst); ROYAL COLLEGE OF SURGEONS IN IRELAND (Inst)
 
Darran O'Connor
Consulting or Advisory Role - Pfizer
 
Ailis Fagan
No Relationships to Disclose
 
Leonie S Young
No Relationships to Disclose
 
Norma O'Donovan
Research Funding - GlaxoSmithKline (Inst)
 
Janice Maria Walshe
Consulting or Advisory Role - AstraZeneca; Pfizer; Roche
Travel, Accommodations, Expenses - Roche
 
Arnold D. Hill
No Relationships to Disclose
 
M. John Kennedy
No Relationships to Disclose
 
Colm Power
No Relationships to Disclose
 
Deirdre Duke
No Relationships to Disclose
 
Niamh Hambly
No Relationships to Disclose
 
William M. Gallagher
Employment - OncoMatrix
Leadership - OncoMatrix
Stock and Other Ownership Interests - OncoMatrix
Patents, Royalties, Other Intellectual Property - OncoMark ; OncoMark (Inst)
 
John Crown
Honoraria - Bayer; Bayer; Eisai; Genomic Health; Genomic Health; New Oncology; New Oncology; New Oncology; Novartis; Pfizer; Teva; Teva; Teva
Consulting or Advisory Role - Bayer; Bayer; Eisai; Genomic Health; Genomic Health; New Oncology; New Oncology; New Oncology; Novartis; Pfizer; Teva; Teva; Teva
Speakers' Bureau - Genomic Health; Pfizer
Research Funding - Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Eisai (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst)
 
Bryan Hennessy
No Relationships to Disclose